Compare Cronos Group Inc (CRON) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Synchrony Financial — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Synchrony Financial trades at $73.83 (market cap $23.99B). The key difference: Synchrony Financial is far larger — about 20.3× Cronos Group Inc's market cap, and Synchrony Financial pays a 1.84% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Synchrony Financial for 28 Days on average.
| CRON | SYF | |
|---|---|---|
Market Cap | $1.18B | $23.99B |
Volume | 968,037 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $3.55 | $88.47 |
52-Week Low | $2.30 | $63.78 |
Typical Hold Time | 22 Days | 28 Days |
Enterprise Value | $387.62M | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $9.45M in 2025 despite revenue growth to $146.59M, but recent quarters show earnings beats. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings. Recent news highlights investor day events and international expansion efforts.
The outlook is cautious; profitability improvements and cash flow generation are key catalysts, but high valuation multiples and negative net cash flow pose risks. Regulatory developments in cannabis markets and execution on growth targets will be critical for stock performance.
SYF trades at $71.93, down 0.32% on the day, with a bearish technical signal from moving averages. The stock is valued attractively with a P/E of 7.38 and P/S of 1.68, supported by strong profitability including a 23.4% net income margin and 22.23% ROE. Recent earnings have consistently beaten estimates, and the company is expanding through partnerships like the Vetspire tie-up and OpenAI collaboration to enhance its digital payment solutions.
The outlook remains positive given the low valuation, high profitability, and strategic growth initiatives. Key risks include potential credit quality deterioration amid economic uncertainty and heavy investing cash outflows. Analyst consensus is bullish with a $88.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
